Kodiak Sciences (NASDAQ:KOD) Director Bros. Advisors Lp Baker Purchases 160,658 Shares of Company Stock

Kodiak Sciences Inc. (NASDAQ:KOD) Director Bros. Advisors Lp Baker purchased 160,658 shares of Kodiak Sciences stock in a transaction that occurred on Wednesday, November 4th. The stock was acquired at an average cost of $98.51 per share, with a total value of $15,826,419.58. Following the transaction, the director owned 20,343,130 shares in the company, valued at $2,004,001,736.30. This trade represents a 0.80% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Thursday, November 5th, Bros. Advisors Lp Baker acquired 86,432 shares of Kodiak Sciences stock. The shares were bought at an average cost of $98.51 per share, for a total transaction of $8,514,416.32.
• On Monday, September 28th, Bros. Advisors Lp Baker acquired 807,840 shares of Kodiak Sciences stock. The shares were bought at an average cost of $72.57 per share, with a total value of $58,624,948.80.
• On Monday, September 28th, Bros. Advisors Lp Baker acquired 418,323 shares of Kodiak Sciences stock. The shares were bought at an average cost of $83.58 per share, with a total value of $34,963,436.34.
• On Tuesday, September 29th, Bros. Advisors Lp Baker purchased 33,726 shares of Kodiak Sciences stock. The shares were purchased at an average price of $85.05 per share, for a total transaction of $2,868,396.30.
• On Monday, September 28th, Bros. Advisors Lp Baker acquired 681,866 shares of Kodiak Sciences stock. The shares were purchased at an average price of $88.77 per share, with a total value of $60,529,244.82.

Kodiak Sciences Stock Performance

NASDAQ:KOD opened at $99.30 on Friday. The firm’s fifty day moving average is $69.56 and its 200-day moving average is $43.69. Kodiak Sciences Inc. has a 52 week low of $15.83 and a 52 week high of $104.00. The firm has a market cap of $6.24 billion, a P/E ratio of -23.70 and a beta of 2.02.

Kodiak Sciences (NASDAQ:KOD) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.09). As a group, sell-side analysts anticipate that Kodiak Sciences Inc. will post -3.97 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of KOD. BlackRock Inc. purchased a new stake in shares of Kodiak Sciences in the second quarter worth about $161,113,000. Jupiter Topco LLC bought a new position in shares of Kodiak Sciences during the second quarter worth about $59,507,000. Janus Henderson Group PLC lifted its position in shares of Kodiak Sciences by 32.5% in the first quarter. Janus Henderson Group PLC now owns 1,325,457 shares of the company’s stock worth $50,540,000 after purchasing an additional 325,457 shares in the last quarter. ICONIQ Capital LLC acquired a new stake in Kodiak Sciences during the second quarter worth about $49,345,000. Finally, Wellington Management Group LLP grew its holdings in Kodiak Sciences by 81.9% during the 2nd quarter. Wellington Management Group LLP now owns 793,613 shares of the company’s stock worth $30,919,000 after acquiring an additional 357,284 shares during the period. Institutional investors own 89.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on KOD shares. JPMorgan Chase & Co. increased their price target on shares of Kodiak Sciences from $56.00 to $66.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. Wall Street Zen raised Kodiak Sciences from a “strong sell” rating to a “sell” rating in a research report on Sunday, October 4th. UBS Group upped their price objective on Kodiak Sciences from $80.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, September 28th. The Goldman Sachs Group began coverage on Kodiak Sciences in a research report on Wednesday, September 30th. They set a “neutral” rating and a $103.00 price target on the stock. Finally, HC Wainwright raised their price objective on Kodiak Sciences from $96.00 to $126.00 and gave the stock a “buy” rating in a research note on Monday, October 12th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $104.71.

About Kodiak Sciences

Kodiak Sciences Inc (NASDAQ: KOD) is a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases. The company’s research centers on therapies designed to address conditions that can cause vision loss, including diabetic macular edema, neovascular age-related macular degeneration and retinal vein occlusion.

Kodiak’s proprietary Antibody Biopolymer Conjugate platform is designed to combine the targeting capabilities of antibody-based medicines with a biodegradable polymer intended to extend the duration of treatment in the eye.